Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 12Colonic Neoplasms 4Rectal Neoplasms 3Neoplasms 3Neoplasm Metastasis 3Solid Tumor Cancer 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Gastric Adenocarcinoma 1Gallbladder Neoplasms 1Bile Duct Neoplasms 1Advanced Solid Tumors 1

Interventions

Gemcitabine 34Cisplatin 21Capecitabine 18Oxaliplatin 15Leucovorin 10Fluorouracil 10Irinotecan 8Erlotinib Hydrochloride 7pembrolizumab 5Bevacizumab 5Radiotherapy 4Carboplatin 4Albumin-Bound Paclitaxel 4130-nm albumin-bound paclitaxel 4Watchful Waiting 3Taxes 3Sorafenib 3Platinum 3Interleukin-12 Subunit p35 3Immunohistochemistry 3Docetaxel 31,2-diaminocyclohexaneplatinum II citrate 3trifluridine tipiracil drug combination 2tremelimumab 2regorafenib 2durvalumab 2dehydroftorafur 2Trastuzumab 2Paclitaxel 2N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Gallbladder Neoplasms × Trifluridine × Clear all
NCT04072445 2023-08-09

Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer

Mayo Clinic

Phase 2 Completed
28 enrolled 20 charts
Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡